Ferric Carboxymaltose
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ferric Carboxymaltose: Bronchitis
One-Sentence Summary
Ferric carboxymaltose is an intravenous iron replacement product, marketed in Australia as Ferinject. The TxGNN model predicts it may be effective for bronchitis (the top-ranked prediction), but there are no registered clinical trials and no publications supporting this direction. The prediction comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, so the evidence is very weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9900 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ferric carboxymaltose is an intravenous iron replacement product. Its role is to correct iron deficiency and iron deficiency anaemia.
No mechanistic link to bronchitis was identified. The drug has no known anti-infective or airway anti-inflammatory activity. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not supported by trials or literature.
Other top-ranked predictions were also reviewed. Most have no plausible therapeutic link either:
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for bronchitis.
For context, literature was retrieved for other predicted indications, none of which supports a repurposing claim:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36282723 | 2023 | Review | Eur Heart J | Iron deficiency is common in cardiovascular disease (thrombotic disease prediction) |
| 41912474 | 2026 | Cohort | Renal Failure | In 41 non-dialysis CKD patients with iron deficiency, IV ferric carboxymaltose was examined for effects on platelet counts and transferrin, with potential thrombogenicity implications |
| 32079699 | 2021 | Preclinical (rat) | Haematologica | Iron deficiency-induced thrombocytosis increased thrombotic tendency; ferric carboxymaltose was used to reverse deficiency |
| 31855154 | 2020 | Cohort | Blood Transfus | IV ferric carboxymaltose was effective and safe for iron deficiency anaemia in inflammatory rheumatic diseases |
| 42785516 | 2026 | Cohort/Review | J Pediatr | Compared effectiveness and safety of IV iron formulations in children with iron deficiency |
| 39304237 | 2024 | RCT | Lancet Glob Health | IV ferric carboxymaltose vs oral ferrous sulphate for anaemia in pregnancy in Nigeria (not relevant to the predicted indications) |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 10104T | Ferinject | Injection 500 mg (iron) in 10 mL | Not available |
Safety Considerations
- Drug Interactions (5 recorded in the interaction database):
- Major: Dimercaprol
- Moderate: Iron, ferrous fumarate, ferrous gluconate, chloramphenicol
- Bone-related signal: Ferric carboxymaltose can cause hypophosphatemia and, with prolonged use, osteomalacia.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction of bronchitis has no clinical trials, no literature and no plausible mechanism, so it rests on a TxGNN model (deep learning) score alone, which may reflect similarities the model learned between related diseases, not biological evidence (Evidence Level L5).
To proceed, the following is needed:
- Mechanism of action data
- Approved indication text and PI warnings and contraindications for the Australian entry
- A plausible mechanistic or clinical rationale for any predicted indication, followed by registered trials or controlled studies
- Route compatibility and similarity-to-original-indication assessments
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.